

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice No: 1818 – October 2018

Ipilimumab (Yervoy®) 5 mg/ml concentrate for solution for infusion

Limited submission by Bristol-Myers Squibb Pharmaceuticals Limited

Recommendation of the All Wales Medicines Strategy Group

Ipilimumab (Yervoy®) is recommended as an option for use within NHS Wales as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to < 18 years of age.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent to or lower than the PAS price.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- AWMSG considered that ipilimumab (Yervoy®) satisfied the AWMSG criteria for an ultra-orphan equivalent medicine.
- AWMSG considered that the AWMSG criteria for appraising life-extending, end-of-life medicines applied to ipilimumab (Yervoy®) for the indication under consideration.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3604), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1818: Ipilimumab (Yervoy®) 5 mg/ml concentrate for solution for infusion.
October 2018